Retifanlimab-dlwr - Biologic Drug Details

Summary for retifanlimab-dlwr

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for retifanlimab-dlwr

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for retifanlimab-dlwr Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for retifanlimab-dlwr Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for retifanlimab-dlwr Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Retifanlimab-dlwr

Last updated: April 9, 2026

What is Retifanlimab-dlwr and its Current Development Status?

Retifanlimab-dlwr (development code: INCMGA0012) is a PD-1 inhibitor developed by Incyte Corporation. It is designed to enhance immune response by blocking the PD-1 pathway, primarily targeting cancers that exhibit high unmet needs.

As of 2023, retifanlimab-dlwr has completed Phase 2 trials for indication in advanced squamous cell carcinoma of the anal canal, with exploratory studies in other solid tumors. The drug has received Fast Track designation for anal canal carcinoma from the FDA but is not yet approved for commercial use.

Market Sizes and Key Players

The PD-1/PD-L1 inhibitor market is dominated by Merck’s pembrolizumab and Bristol-Myers Squibb’s nivolumab. Combined, these drugs generated approximately $30 billion in global revenue in 2022, with key indications including melanoma, non-small cell lung cancer (NSCLC), and bladder cancer.

The anal cancer segment, retifanlimab’s primary target, accounts for a small fraction of the PD-1 market. It is estimated to reach $200 million by 2028, driven by an increase in incidence and unmet medical needs.

Competitive landscape comparison:

Drug	Indications	Revenue (2022)	Approval Status
Pembrolizumab	Multiple solid tumors	$22.4 billion	Approved globally
Nivolumab	Multiple solid tumors	$8.2 billion	Approved globally
Retifanlimab	Anal cancer (pending approval)	N/A	Phase 2, under review

Financial Trajectory and Revenue Forecasts

Retifanlimab-dlwr is in clinical development, with potential approval likely contingent upon successful outcomes in Phase 3 trials. The drug’s future revenue hinges on several factors:

• Regulatory approval timeline: If approved in 2024, commercial launch would follow within six to 12 months.
• Pricing assumptions: Similar drugs pricing range from $10,000 to $15,000 per month, or up to $180,000 annually per patient.
• Market penetration: Expected initial market penetration is 10-15% within five years of launch, considering competition and diagnosis rates.

Revenue projection example (assuming approval in 2024):

Year	Estimated Patients	Market Penetration	Revenue Estimate
2024	1,000	0%	$0
2025	3,000	10%	$5 million
2026	5,000	15%	$14 million
2027	7,000	15%	$25 million
2028	10,000	15%	$35 million

These forecasts assume successful regulatory review and market acceptance, but actual outcomes depend on clinical trial results, approval speed, payer negotiations, and competitive responses.

Challenges and Risks

• Clinical efficacy: Expectation that Phase 3 results demonstrate significant benefit over existing therapies.
• Regulatory hurdles: FDA review delays or safety concerns could slow commercialization.
• Market competition: Larger players with established PD-1 inhibitors could limit growth.
• Pricing and reimbursement: Payor resistance may constrain revenue, especially if pricing exceeds benchmarks.

Market Entry Strategies

Incyte’s potential strategies include:

• Focused approval for high-incidence regions.
• Collaborations with specialty oncology centers.
• Advocacy for expanded indications based on trial data.
• Competitive pricing and patient access programs to secure market share.

Key Takeaways

• Retifanlimab-dlwr is a PD-1 inhibitor in late-stage clinical development targeting anal carcinoma.
• The PD-1/PD-L1 market is dominated by pembrolizumab and nivolumab, with combined revenues of over $30 billion in 2022.
• Retifanlimab’s market size is small but growing; projected to reach $200 million by 2028.
• Financial success depends on clinical trial outcomes, approval timing, payer acceptance, and competitive dynamics.
• The drug faces challenges from established competitors, regulatory processes, and healthcare reimbursement policies.

FAQs

1. When could retifanlimab-dlwr realistically enter the market?
Potential approval could occur in late 2024 if Phase 3 trials are successful, with commercialization possibly beginning by 2025.

2. How does the pricing of retifanlimab compare to other PD-1 inhibitors?
Similar to existing drugs, with monthly costs ranging from $10,000 to $15,000, depending on dosage and market conditions.

3. What is the primary clinical indication for retifanlimab?
Advanced squamous cell carcinoma of the anal canal.

4. What are key risks associated with retifanlimab's market success?
Clinical trial failure, regulatory delays, competitive influx, and reimbursement restrictions.

5. Who are the main competitors in the PD-1 space?
Merck's pembrolizumab and Bristol-Myers Squibb’s nivolumab.

References

[1] Incyte Corporation. (2022). Clinical trial data and development updates.
[2] IQVIA. (2022). Global Oncology Market Report.
[3] EvaluatePharma. (2022). Oncology drug sales review.
[4] FDA. (2023). Fast Track Designations and Approvals.